assig PathoW6M5

Write a 1- to 2-page summary paper that addresses the following: + title, + introduction, + conclusion, and references pages) Please make sure to include dosing and side effects in your assignment.    

· Briefly summarize the patient case study you were assigned, including each of the three decisions you took for the patient presented.

· Based on the decisions you recommended for the patient case study, explain whether you believe the decisions provided were supported by the evidence-based literature. Be specific and provide examples. Be sure to support your response with evidence and references from outside resources.

· What were you hoping to achieve with the decisions you recommended for the patient case study you were assigned? Support your response with evidence and references from outside resources.

· Explain any difference between what you expected to achieve with each of the decisions and the results of the decision in the exercise. Describe whether they were different. Be specific and provide examples.

· Develop the work, putting each question with its answer individually, Not explain altogether.

· using formal APA writing convention, using the 7th Edition

· References at least 4 and not more than 5 years ago

· Medication: generic name (brand name) ..acetaminophen (Tylenol)

· Plagiarism document…. Thank you

Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.) St. Louis, MO: Elsevier.

· Chapter 11, “Basic Principles of Neuropharmacology” (pp. 67–71)

· Chapter 12, “Physiology of the Peripheral Nervous System” (pp. 72–81)

· Chapter 12, “Muscarinic Agonists and Cholinesterase Inhibitors” (pp. 82–89)

· Chapter 14, “Muscarinic Antagonists” (pp. 90-98)

· Chapter 15, “Adrenergic Agonists” (pp. 99–107)

· Chapter 16, “Adrenergic Antagonists” (pp. 108–119)

· Chapter 17, “Indirect-Acting Antiadrenergic Agents” (pp. 120–124)

· Chapter 18, “Introduction to Central Nervous System Pharmacology” (pp. 125–126)

· Chapter 19, “Drugs for Parkinson Disease” (pp. 127–142)

· Chapter 20, “Drugs for Alzheimer Disease” (pp. 159–166)

· Chapter 21, “Drugs for Seizure Disorders” (pp. 150–170)

· Chapter 22, “Drugs for Muscle Spasm and Spasticity” (pp. 171–178)

· Chapter 24, “Opioid Analgesics, Opioid Antagonists, and Nonopioid Centrally Acting Analgesics” (pp. 183–194)

· Chapter 59, “Drug Therapy of Rheumatoid Arthritis” (pp. 513–527)

· Chapter 60, “Drug Therapy of Gout” (pp. 528–536)

· Chapter 61, “Drugs Affecting Calcium Levels and Bone Mineralization” (pp. 537–556)